PanGen Biotech Inc. (KOSDAQ:222110)

Market Cap	80.83B +35.4%
Revenue (ttm)	13.42B -8.6%
Net Income	2.05B +117.3%
EPS	146.00 +78.0%
Shares Out	13.49M
PE Ratio	41.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	107,520
Average Volume	335,497
Open	6,150.00
Previous Close	6,080.00
Day's Range	5,940.00 - 6,160.00
52-Week Range	4,505.00 - 8,510.00
Beta	-0.17
RSI	53.63
Earnings Date	n/a

About PanGen Biotech

PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, as well as technology transfer service. PanGen Biotech Inc. was founded in 1999 and is based in Suwon-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 222110

Financial Performance

In 2025, PanGen Biotech's revenue was 13.42 billion, a decrease of -8.56% compared to the previous year's 14.67 billion. Earnings were 2.05 billion, an increase of 117.30%.